Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)

M. Navazesh, R. Mulligan, R. Karim, W. J. Mack, S. Ram, H. Seirawan, J. Greenspan, D. Greenspan, J. Phelan, M. Alves, Joan Phelan, Anthony Vernillo, Manley LaMarre, Deborah Greenspan, John S. Greenspan, Laurie A. Macphail, Roseann Mulligan, Mahvash Navazesh, Joyce Galligan, Lupe ArevaloWendy Mack, Roksana Karim, Saravanan Ram, Hazem Seirawan, Sharon Bautista-King, Claudia Vargas, Mario Alves, Stephen J. Gange, Yolanda Barron, Maryann Redford

Research output: Contribution to journalArticle

Abstract

Objective: To determine the impact of highly active antiretroviral therapy (HAART) on salivary gland function in human immunodeficiency virus (HIV) positive women from the Women's Interagency HIV Study (WIHS). Design: Longitudinal cohort study. Subjects and methods: A total of 668 HIV positive women from the WIHS cohort with an initial and at least one follow-up oral sub-study visit contributed 5358 visits. Salivary gland function was assessed based on a dry mouth questionnaire, whole unstimulated and stimulated salivary flow rates, salivary gland enlargement or tenderness and lack of saliva on palpation of the major salivary glands. Main outcome measures: Changes in unstimulated and stimulated flow rates at any given visit from that of the immediate prior visit (continuous variables). The development of self-reported dry mouth (present/absent), enlargement or tenderness of salivary glands (present/absent), and absence of secretion on palpation of the salivary glands were binary outcomes (yes/no). Results: Protease Inhibitor (PI) based HAART was a significant risk factor for developing decreased unstimulated (P = 0.01) and stimulated (P = 0.0004) salivary flow rates as well as salivary gland enlargement (P = 0.006) as compared with non-PI based HAART. Conclusions: PI-based HAART therapy is a significant risk factor for developing reduced salivary flow rates and salivary gland enlargement in HIV positive patients.

Original languageEnglish (US)
Pages (from-to)52-60
Number of pages9
JournalOral Diseases
Volume15
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Highly Active Antiretroviral Therapy
Salivary Glands
HIV
Palpation
Protease Inhibitors
Mouth
Cohort Studies
Saliva
Longitudinal Studies
Outcome Assessment (Health Care)

Keywords

  • Antiretroviral therapy
  • HAART
  • HIV
  • PI based HAART
  • Salivary gland enlargement
  • Salivary gland function

ASJC Scopus subject areas

  • Dentistry(all)
  • Otorhinolaryngology

Cite this

Navazesh, M., Mulligan, R., Karim, R., Mack, W. J., Ram, S., Seirawan, H., ... Redford, M. (2009). Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). Oral Diseases, 15(1), 52-60. https://doi.org/10.1111/j.1601-0825.2008.01456.x

Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). / Navazesh, M.; Mulligan, R.; Karim, R.; Mack, W. J.; Ram, S.; Seirawan, H.; Greenspan, J.; Greenspan, D.; Phelan, J.; Alves, M.; Phelan, Joan; Vernillo, Anthony; LaMarre, Manley; Greenspan, Deborah; Greenspan, John S.; Macphail, Laurie A.; Mulligan, Roseann; Navazesh, Mahvash; Galligan, Joyce; Arevalo, Lupe; Mack, Wendy; Karim, Roksana; Ram, Saravanan; Seirawan, Hazem; Bautista-King, Sharon; Vargas, Claudia; Alves, Mario; Gange, Stephen J.; Barron, Yolanda; Redford, Maryann.

In: Oral Diseases, Vol. 15, No. 1, 01.2009, p. 52-60.

Research output: Contribution to journalArticle

Navazesh, M, Mulligan, R, Karim, R, Mack, WJ, Ram, S, Seirawan, H, Greenspan, J, Greenspan, D, Phelan, J, Alves, M, Phelan, J, Vernillo, A, LaMarre, M, Greenspan, D, Greenspan, JS, Macphail, LA, Mulligan, R, Navazesh, M, Galligan, J, Arevalo, L, Mack, W, Karim, R, Ram, S, Seirawan, H, Bautista-King, S, Vargas, C, Alves, M, Gange, SJ, Barron, Y & Redford, M 2009, 'Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)', Oral Diseases, vol. 15, no. 1, pp. 52-60. https://doi.org/10.1111/j.1601-0825.2008.01456.x
Navazesh, M. ; Mulligan, R. ; Karim, R. ; Mack, W. J. ; Ram, S. ; Seirawan, H. ; Greenspan, J. ; Greenspan, D. ; Phelan, J. ; Alves, M. ; Phelan, Joan ; Vernillo, Anthony ; LaMarre, Manley ; Greenspan, Deborah ; Greenspan, John S. ; Macphail, Laurie A. ; Mulligan, Roseann ; Navazesh, Mahvash ; Galligan, Joyce ; Arevalo, Lupe ; Mack, Wendy ; Karim, Roksana ; Ram, Saravanan ; Seirawan, Hazem ; Bautista-King, Sharon ; Vargas, Claudia ; Alves, Mario ; Gange, Stephen J. ; Barron, Yolanda ; Redford, Maryann. / Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). In: Oral Diseases. 2009 ; Vol. 15, No. 1. pp. 52-60.
@article{8b1c7dff3fff472d8c9edeb6b1b28807,
title = "Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)",
abstract = "Objective: To determine the impact of highly active antiretroviral therapy (HAART) on salivary gland function in human immunodeficiency virus (HIV) positive women from the Women's Interagency HIV Study (WIHS). Design: Longitudinal cohort study. Subjects and methods: A total of 668 HIV positive women from the WIHS cohort with an initial and at least one follow-up oral sub-study visit contributed 5358 visits. Salivary gland function was assessed based on a dry mouth questionnaire, whole unstimulated and stimulated salivary flow rates, salivary gland enlargement or tenderness and lack of saliva on palpation of the major salivary glands. Main outcome measures: Changes in unstimulated and stimulated flow rates at any given visit from that of the immediate prior visit (continuous variables). The development of self-reported dry mouth (present/absent), enlargement or tenderness of salivary glands (present/absent), and absence of secretion on palpation of the salivary glands were binary outcomes (yes/no). Results: Protease Inhibitor (PI) based HAART was a significant risk factor for developing decreased unstimulated (P = 0.01) and stimulated (P = 0.0004) salivary flow rates as well as salivary gland enlargement (P = 0.006) as compared with non-PI based HAART. Conclusions: PI-based HAART therapy is a significant risk factor for developing reduced salivary flow rates and salivary gland enlargement in HIV positive patients.",
keywords = "Antiretroviral therapy, HAART, HIV, PI based HAART, Salivary gland enlargement, Salivary gland function",
author = "M. Navazesh and R. Mulligan and R. Karim and Mack, {W. J.} and S. Ram and H. Seirawan and J. Greenspan and D. Greenspan and J. Phelan and M. Alves and Joan Phelan and Anthony Vernillo and Manley LaMarre and Deborah Greenspan and Greenspan, {John S.} and Macphail, {Laurie A.} and Roseann Mulligan and Mahvash Navazesh and Joyce Galligan and Lupe Arevalo and Wendy Mack and Roksana Karim and Saravanan Ram and Hazem Seirawan and Sharon Bautista-King and Claudia Vargas and Mario Alves and Gange, {Stephen J.} and Yolanda Barron and Maryann Redford",
year = "2009",
month = "1",
doi = "10.1111/j.1601-0825.2008.01456.x",
language = "English (US)",
volume = "15",
pages = "52--60",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)

AU - Navazesh, M.

AU - Mulligan, R.

AU - Karim, R.

AU - Mack, W. J.

AU - Ram, S.

AU - Seirawan, H.

AU - Greenspan, J.

AU - Greenspan, D.

AU - Phelan, J.

AU - Alves, M.

AU - Phelan, Joan

AU - Vernillo, Anthony

AU - LaMarre, Manley

AU - Greenspan, Deborah

AU - Greenspan, John S.

AU - Macphail, Laurie A.

AU - Mulligan, Roseann

AU - Navazesh, Mahvash

AU - Galligan, Joyce

AU - Arevalo, Lupe

AU - Mack, Wendy

AU - Karim, Roksana

AU - Ram, Saravanan

AU - Seirawan, Hazem

AU - Bautista-King, Sharon

AU - Vargas, Claudia

AU - Alves, Mario

AU - Gange, Stephen J.

AU - Barron, Yolanda

AU - Redford, Maryann

PY - 2009/1

Y1 - 2009/1

N2 - Objective: To determine the impact of highly active antiretroviral therapy (HAART) on salivary gland function in human immunodeficiency virus (HIV) positive women from the Women's Interagency HIV Study (WIHS). Design: Longitudinal cohort study. Subjects and methods: A total of 668 HIV positive women from the WIHS cohort with an initial and at least one follow-up oral sub-study visit contributed 5358 visits. Salivary gland function was assessed based on a dry mouth questionnaire, whole unstimulated and stimulated salivary flow rates, salivary gland enlargement or tenderness and lack of saliva on palpation of the major salivary glands. Main outcome measures: Changes in unstimulated and stimulated flow rates at any given visit from that of the immediate prior visit (continuous variables). The development of self-reported dry mouth (present/absent), enlargement or tenderness of salivary glands (present/absent), and absence of secretion on palpation of the salivary glands were binary outcomes (yes/no). Results: Protease Inhibitor (PI) based HAART was a significant risk factor for developing decreased unstimulated (P = 0.01) and stimulated (P = 0.0004) salivary flow rates as well as salivary gland enlargement (P = 0.006) as compared with non-PI based HAART. Conclusions: PI-based HAART therapy is a significant risk factor for developing reduced salivary flow rates and salivary gland enlargement in HIV positive patients.

AB - Objective: To determine the impact of highly active antiretroviral therapy (HAART) on salivary gland function in human immunodeficiency virus (HIV) positive women from the Women's Interagency HIV Study (WIHS). Design: Longitudinal cohort study. Subjects and methods: A total of 668 HIV positive women from the WIHS cohort with an initial and at least one follow-up oral sub-study visit contributed 5358 visits. Salivary gland function was assessed based on a dry mouth questionnaire, whole unstimulated and stimulated salivary flow rates, salivary gland enlargement or tenderness and lack of saliva on palpation of the major salivary glands. Main outcome measures: Changes in unstimulated and stimulated flow rates at any given visit from that of the immediate prior visit (continuous variables). The development of self-reported dry mouth (present/absent), enlargement or tenderness of salivary glands (present/absent), and absence of secretion on palpation of the salivary glands were binary outcomes (yes/no). Results: Protease Inhibitor (PI) based HAART was a significant risk factor for developing decreased unstimulated (P = 0.01) and stimulated (P = 0.0004) salivary flow rates as well as salivary gland enlargement (P = 0.006) as compared with non-PI based HAART. Conclusions: PI-based HAART therapy is a significant risk factor for developing reduced salivary flow rates and salivary gland enlargement in HIV positive patients.

KW - Antiretroviral therapy

KW - HAART

KW - HIV

KW - PI based HAART

KW - Salivary gland enlargement

KW - Salivary gland function

UR - http://www.scopus.com/inward/record.url?scp=57549086618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549086618&partnerID=8YFLogxK

U2 - 10.1111/j.1601-0825.2008.01456.x

DO - 10.1111/j.1601-0825.2008.01456.x

M3 - Article

VL - 15

SP - 52

EP - 60

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 1

ER -